目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 34)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS OF THE STUDY
1.2.2 MARKETS COVERED
FIGURE 1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SEGMENTATION
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 38)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 2 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Market estimation from the parent market
FIGURE 6 BOTTOM-UP APPROACH: MARKET ESTIMATION FROM THE PARENT MARKET
2.3.1.3 Approach 3: Presentations of companies and primary interviews
2.3.1.4 Growth forecast
2.3.1.5 CAGR projections
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 8 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ANALYSIS
2.6 ASSUMPTIONS FOR THE STUDY
2.7 RISK ASSESSMENT
2.7.1 RISK ASSESSMENT: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
2.8 GROWTH RATE ASSUMPTIONS
2.9 COVID-19 HEALTH ASSESSMENT
2.10 COVID-19 ECONOMIC ASSESSMENT
2.11 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
FIGURE 10 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 11 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
2.12 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET

3 EXECUTIVE SUMMARY (Page No. - 53)
FIGURE 12 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
FIGURE 13 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
FIGURE 14 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 15 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 16 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 58)
4.1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET OVERVIEW
FIGURE 17 RISING ADOPTION OF POC DIAGNOSTICS TO SUPPORT MARKET GROWTH DURING THE FORECAST PERIOD
4.2 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026
FIGURE 18 ASSAYS & KITS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
4.3 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY, 2021 VS. 2026
FIGURE 19 RT-PCR SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
4.4 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY APPLICATION, 2021 VS. 2026
FIGURE 20 RESPIRATORY DISEASES SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
4.5 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY END USER, 2021 VS. 2026
FIGURE 21 PHYSICIANS’ OFFICES SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
4.6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 22 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 62)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 23 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of infectious diseases and cancer
5.2.1.2 Rising focus on decentralized diagnostics and increasing R&D funding
5.2.1.3 Increasing awareness on the early detection of infectious diseases
5.2.1.4 Increasing use of POC diagnostic tests
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement scenario
5.2.2.2 High capital investments and low cost-benefit ratio
5.2.3 OPPORTUNITIES
5.2.3.1 Growing R&D activities in point-of-care molecular diagnostics testing
5.2.3.2 Growth opportunities in emerging countries
5.2.4 CHALLENGES
5.2.4.1 Stringent and time-consuming regulatory policies that significantly increase the product launch cycle
5.2.4.2 Introduction of alternative technologies
5.3 IMPACT OF COVID-19 ON THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
5.4 PRICING ANALYSIS
TABLE 1 PRICES OF POINT-OF-CARE MOLECULAR DIAGNOSTIC PRODUCTS (2021)
5.5 PATENT ANALYSIS
5.6 TRADE ANALYSIS
5.6.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
TABLE 2 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016-2020 (USD MILLION)
TABLE 3 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016-2020 (USD MILLION)
5.7 VALUE CHAIN ANALYSIS
FIGURE 24 MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASES
5.8 SUPPLY CHAIN ANALYSIS
FIGURE 25 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES
5.9 ECOSYSTEM ANALYSIS
FIGURE 26 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
5.9.1 ROLE IN THE ECOSYSTEM
5.10 PORTER’S FIVE FORCES ANALYSIS
TABLE 4 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.10.1 THREAT FROM NEW ENTRANTS
5.10.2 THREAT FROM SUBSTITUTES
5.10.3 BARGAINING POWER OF BUYERS
5.10.4 BARGAINING POWER OF SUPPLIERS
5.10.5 DEGREE OF COMPETITION
5.11 PESTLE ANALYSIS
5.12 REGULATORY LANDSCAPE
5.12.1 NORTH AMERICA
5.12.1.1 US
5.12.1.2 CANADA
5.12.2 EUROPE
5.12.3 ASIA PACIFIC
5.12.3.1 Japan
5.12.3.2 India
5.12.3.3 China
5.12.4 LATIN AMERICA
5.12.4.1 Brazil
5.12.4.2 Mexico
5.12.5 MIDDLE EAST
5.12.6 AFRICA
5.13 TECHNOLOGY ANALYSIS
5.14 DISRUPTIVE TECHNOLOGIES IN THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
5.14.1 REVENUE SHIFT AND REVENUE POCKETS FOR THE POC MOLECULAR DIAGNOSTICS MARKET
FIGURE 27 REVENUE SHIFT FOR THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET

6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 81)
6.1 INTRODUCTION
TABLE 5 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018-2020 (USD MILLION)
TABLE 6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
6.2 ASSAYS & KITS
6.2.1 RECURRENT PURCHASE OF ASSAYS & KITS IS A MAJOR FACTOR DRIVING MARKET GROWTH
TABLE 7 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY REGION, 2018-2020 (USD MILLION)
TABLE 8 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY REGION, 2021-2026 (USD MILLION)
6.3 INSTRUMENTS & ANALYZERS
6.3.1 INCREASING ADOPTION OF POC TECHNOLOGIES TO DRIVE GROWTH IN THIS MARKET SEGMENT
TABLE 9 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY REGION, 2018-2020 (USD MILLION)
TABLE 10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY REGION, 2021-2026 (USD MILLION)
6.4 SOFTWARE & SERVICES
6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE GROWTH IN THIS MARKET SEGMENT
TABLE 11 POINT-OF-CARE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2018-2020 (USD MILLION)
TABLE 12 POINT-OF-CARE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021-2026 (USD MILLION)

7 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 87)
7.1 INTRODUCTION
TABLE 13 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 14 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
7.2 RT-PCR
7.2.1 GROWING USE OF RT-PCR IN COVID-19 TESTING IS A MAJOR DRIVER FOR THIS SEGMENT
TABLE 15 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2018-2020 (USD MILLION)
TABLE 16 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2021-2026 (USD MILLION)
7.3 INAAT
7.3.1 COST BENEFITS OF INAAT ARE A KEY FACTOR DRIVING MARKET GROWTH
TABLE 17 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2018-2020 (USD MILLION)
TABLE 18 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2021-2026 (USD MILLION)
7.4 OTHER TECHNOLOGIES
TABLE 19 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2018-2020 (USD MILLION)
TABLE 20 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021-2026 (USD MILLION)

8 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (Page No. - 93)
8.1 INTRODUCTION
TABLE 21 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018-2020 (USD MILLION)
TABLE 22 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2026 (USD MILLION)
8.2 RESPIRATORY DISEASES
8.2.1 GROWING PREVALENCE OF COVID-19 TO DRIVE GROWTH IN THIS MARKET SEGMENT
TABLE 23 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2018-2020 (USD MILLION)
TABLE 24 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2021-2026 (USD MILLION)
8.3 SEXUALLY TRANSMITTED DISEASES
8.3.1 TECHNOLOGICAL ADVANCEMENTS FOR THE DETECTION OF STDS PLAY A MAJOR ROLE IN DRIVING THE GROWTH OF THIS MARKET
TABLE 25 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2018-2020 (USD MILLION)
TABLE 26 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SEXUALLY TRANSMITTED DISEASES, BY REGION, 2021-2026 (USD MILLION)
8.4 HOSPITAL-ACQUIRED INFECTIONS
8.4.1 RISING BURDEN OF MRSA WILL DRIVE THE GROWTH OF THE MARKET IN THE COMING YEARS
TABLE 27 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2018-2020 (USD MILLION)
TABLE 28 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2021-2026 (USD MILLION)
8.5 CANCER
8.5.1 RISING PREVALENCE OF CANCER AND GROWING FUNDING FOR CANCER RESEARCH TO DRIVE MARKET GROWTH
TABLE 29 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2018-2020 (USD MILLION)
TABLE 30 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2021-2026 (USD MILLION)
8.6 HEPATITIS
8.6.1 INCREASE IN CASES OF HEPATITIS AMONG HIGH-RISK SUBGROUP POPULATIONS TO DRIVE MARKET GROWTH
TABLE 31 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2018-2020 (USD MILLION)
TABLE 32 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2021-2026 (USD MILLION)
8.7 GASTROINTESTINAL DISORDERS
8.7.1 INCREASE CASES OF GASTROINTESTINAL DISORDERS TO DRIVE MARKET GROWTH
TABLE 33 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2018-2020 (USD MILLION)
TABLE 34 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2021-2026 (USD MILLION)
8.8 OTHER APPLICATIONS
TABLE 35 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2018-2020 (USD MILLION)
TABLE 36 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2026 (USD MILLION)

9 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER (Page No. - 105)
9.1 INTRODUCTION
TABLE 37 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 38 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
9.2 PHYSICIANS’ OFFICES
9.2.1 EARLY RESULTS OF POINT-OF-CARE MOLECULAR ASSAYS TO DRIVE GROWTH IN THIS MARKET
TABLE 39 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES, BY REGION, 2018-2020 (USD MILLION)
TABLE 40 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES, BY REGION, 2021-2026 (USD MILLION)
9.3 HOSPITALS & ICUS
TABLE 41 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY DISEASE TYPE, 2018-2020 (USD MILLION)
TABLE 42 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY DISEASE TYPE, 2021-2026 (USD MILLION)
TABLE 43 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY REGION, 2018-2020 (USD MILLION)
TABLE 44 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY REGION, 2021-2026 (USD MILLION)
9.3.1 SEPSIS
9.3.1.1 Growing need for quick diagnosis and treatment will drive growth in this market
TABLE 45 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS, BY REGION, 2018-2020 (USD MILLION)
TABLE 46 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS, BY REGION, 2021-2026 (USD MILLION)
9.3.2 GASTROENTERITIS
9.3.2.1 Increasing number of gastroenteritis cases in hospital emergency departments to propel growth in this market
TABLE 47 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROENTERITIS, BY REGION, 2018-2020 (USD MILLION)
TABLE 48 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROENTERITIS, BY REGION, 2021-2026 (USD MILLION)
9.3.3 MENINGOENCEPHALITIS
9.3.3.1 Severity of the disease and the need for early disease diagnosis to drive market growth
TABLE 49 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR MENINGOENCEPHALITIS, BY REGION, 2018-2020 (USD MILLION)
TABLE 50 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR MENINGOENCEPHALITIS, BY REGION, 2021-2026 (USD MILLION)
9.3.4 OTHER DISEASES
TABLE 51 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER DISEASES, BY REGION, 2018-2020 (USD MILLION)
TABLE 52 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER DISEASES, BY REGION, 2021-2026 (USD MILLION)
9.4 RESEARCH INSTITUTES
9.4.1 INCREASING USE OF POC MOLECULAR DIAGNOSTICS TESTS IN GENOMICS RESEARCH WILL DRIVE THIS MARKET SEGMENT
TABLE 53 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2018-2020 (USD MILLION)
TABLE 54 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2021-2026 (USD MILLION)
9.5 OTHER END USERS
TABLE 55 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2018-2020 (USD MILLION)
TABLE 56 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021-2026 (USD MILLION)

10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION (Page No. - 116)
10.1 INTRODUCTION
TABLE 57 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2018-2020 (USD MILLION)
TABLE 58 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2021-2026 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 28 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
TABLE 59 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 60 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021-2026 (USD MILLION)
TABLE 61 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018-2020 (USD MILLION)
TABLE 62 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 63 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 64 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 65 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018-2020 (USD MILLION)
TABLE 66 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2026 (USD MILLION)
TABLE 67 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 68 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.2.1 US
10.2.1.1 Increasing prevalence of infectious diseases—a key factor driving market growth in the US
TABLE 69 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018-2020 (USD MILLION)
TABLE 70 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 71 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 72 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 73 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018-2020 (USD MILLION)
TABLE 74 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2026 (USD MILLION)
TABLE 75 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 76 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Rising patient population in Canada to drive market growth in the coming years
TABLE 77 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018-2020 (USD MILLION)
TABLE 78 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 79 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 80 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 81 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018-2020 (USD MILLION)
TABLE 82 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2026 (USD MILLION)
TABLE 83 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 84 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.3 EUROPE
TABLE 85 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 86 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021-2026 (USD MILLION)
TABLE 87 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018-2020 (USD MILLION)
TABLE 88 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 89 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 90 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 91 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018-2020 (USD MILLION)
TABLE 92 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2026 (USD MILLION)
TABLE 93 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 94 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Increasing healthcare expenditure to drive market growth in Germany
TABLE 95 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018-2020 (USD MILLION)
TABLE 96 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 97 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 98 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 99 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018-2020 (USD MILLION)
TABLE 100 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2026 (USD MILLION)
TABLE 101 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 102 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.3.2 FRANCE
10.3.2.1 Rising R&D expenditure in France to drive market growth
TABLE 103 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018-2020 (USD MILLION)
TABLE 104 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 105 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 106 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 107 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018-2020 (USD MILLION)
TABLE 108 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2026 (USD MILLION)
TABLE 109 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 110 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.3.3 ITALY
10.3.3.1 Adoption of advanced diagnostic technologies to drive market growth in Italy
TABLE 111 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018-2020 (USD MILLION)
TABLE 112 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 113 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 114 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 115 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018-2020 (USD MILLION)
TABLE 116 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2026 (USD MILLION)
TABLE 117 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 118 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.3.4 UK
10.3.4.1 Increasing prevalence of infectious diseases to drive market growth in the UK
TABLE 119 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018-2020 (USD MILLION)
TABLE 120 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 121 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 122 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 123 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018-2020 (USD MILLION)
TABLE 124 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2026 (USD MILLION)
TABLE 125 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 126 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.3.5 REST OF EUROPE
TABLE 127 ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018-2020 (USD MILLION)
TABLE 128 ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 129 ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 130 ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 131 ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018-2020 (USD MILLION)
TABLE 132 ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2026 (USD MILLION)
TABLE 133 ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 134 ROE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 29 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
TABLE 135 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2018-2020 (USD MILLION)
TABLE 136 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021-2026 (USD MILLION)
TABLE 137 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018-2020 (USD MILLION)
TABLE 138 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 139 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 140 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 141 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018-2020 (USD MILLION)
TABLE 142 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2026 (USD MILLION)
TABLE 143 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 144 APAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.4.1 CHINA
10.4.1.1 Growing public access to modern healthcare and the outbreak of COVID-19 to drive market growth
TABLE 145 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018-2020 (USD MILLION)
TABLE 146 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 147 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 148 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 149 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018-2020 (USD MILLION)
TABLE 150 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2026 (USD MILLION)
TABLE 151 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 152 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Universal healthcare reimbursement policy to drive market growth in Japan
TABLE 153 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018-2020 (USD MILLION)
TABLE 154 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 155 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 156 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 157 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018-2020 (USD MILLION)
TABLE 158 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2026 (USD MILLION)
TABLE 159 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 160 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Increasing private & public investments in the country’s healthcare system will drive market growth
TABLE 161 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018-2020 (USD MILLION)
TABLE 162 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 163 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 164 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 165 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018-2020 (USD MILLION)
TABLE 166 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2026 (USD MILLION)
TABLE 167 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 168 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC (ROAPAC)
TABLE 169 ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018-2020 (USD MILLION)
TABLE 170 ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 171 ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 172 ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 173 ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018-2020 (USD MILLION)
TABLE 174 ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2026 (USD MILLION)
TABLE 175 ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 176 ROAPAC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
10.5 REST OF THE WORLD
TABLE 177 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2018-2020 (USD MILLION)
TABLE 178 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
TABLE 179 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2020 (USD MILLION)
TABLE 180 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
TABLE 181 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018-2020 (USD MILLION)
TABLE 182 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2026 (USD MILLION)
TABLE 183 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018-2020 (USD MILLION)
TABLE 184 ROW: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 176)
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
TABLE 185 STRATEGIES ADOPTED BY KEY POINT-OF-CARE MOLECULAR DIAGNOSTICS MANUFACTURING COMPANIES
11.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
FIGURE 30 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET (2015-2020)
11.4 MARKET SHARE ANALYSIS
TABLE 186 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION QUADRANT
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 32 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT, 2020
11.6 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES (2020)
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 33 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
11.7 COMPETITIVE BENCHMARKING
FIGURE 34 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET
TABLE 187 COMPANY PRODUCT FOOTPRINT
TABLE 188 COMPANY REGIONAL FOOTPRINT
11.8 COMPETITIVE SCENARIO
11.8.1 PRODUCT LAUNCHES & APPROVALS
TABLE 189 KEY PRODUCT LAUNCHES & APPROVALS
11.8.2 DEALS
TABLE 190 KEY DEALS

12 COMPANY PROFILES (Page No. - 187)
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 ABBOTT LABORATORIES
TABLE 191 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
12.1.2 F. HOFFMANN-LA ROCHE LTD.
TABLE 192 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
12.1.3 BIOMÉRIEUX SA
TABLE 193 BIOMÉRIEUX SA: BUSINESS OVERVIEW
FIGURE 37 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2020)
12.1.4 DANAHER CORPORATION
TABLE 194 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 38 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
12.1.5 QUIDEL CORPORATION
TABLE 195 QUIDEL CORPORATION: BUSINESS OVERVIEW
FIGURE 39 QUIDEL CORPORATION: COMPANY SNAPSHOT (2020)
12.1.6 QIAGEN N.V.
TABLE 196 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 40 QIAGEN N.V.: COMPANY SNAPSHOT (2020)
12.1.7 CO-DIAGNOSTICS, INC.
TABLE 197 CO-DIAGNOSTICS, INC.: BUSINESS OVERVIEW
FIGURE 41 CO-DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2020)
12.1.8 BIOCARTIS NV
TABLE 198 BIOCARTIS NV: BUSINESS OVERVIEW
FIGURE 42 BIOCARTIS NV: COMPANY SNAPSHOT (2020)
12.1.9 MERIDIAN BIOSCIENCE, INC.
TABLE 199 MERIDIAN BIOSCIENCE, INC.: BUSINESS OVERVIEW
FIGURE 43 MERIDIAN BIOSCIENCE, INC.: COMPANY SNAPSHOT (2020)
12.1.10 THERMO FISHER SCIENTIFIC INC.
TABLE 200 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2020)
12.2 OTHER PLAYERS
12.2.1 LUCIRA HEALTH, INC.
12.2.2 CUE HEALTH
12.2.3 OPGEN, INC.
12.2.4 BINX HEALTH, INC.
12.2.5 MOLBIO DIAGNOSTICS PVT. LTD.
12.2.6 GENOMADIX
12.2.7 VISBY MEDICAL, INC.
12.2.8 QUIKPATH PTE. LTD.
12.2.9 MD-BIO
12.2.10 QUANTUMDX GROUP LTD.
12.2.11 AIDIAN OY
12.2.12 GENESTAT MOLECULAR DIAGNOSTICS, LLC
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX (Page No. - 227)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS